| Measurability of lesion at baseline |
1. 18F-FDG–avid |
1. 18F-FDG–avid tumor; baseline PET scan is desirable |
|
2. Standardized display with normalization to liver |
2. Variably 18F-FDG–avid tumor; 18F-FDG baseline PET scan is required |
|
|
3. Follow-up PET at least 3 wk after last chemotherapy session or at least 8–12 wk after last radiation therapy session |
|
| Objective response |
Complete metabolic response: 18F-FDG–avid lesions revert to background of normal tissues in which they are located |
Complete response in 18F-FDG–avid tumors: no focal or diffuse increased 18F-FDG uptake over background in location consistent with tumor, regardless of CT abnormality; new lung nodules in lymphoma patient without history of lung involvement (regardless of 18F-FDG avidity) are not considered lymphoma; increased focal or multifocal marrow uptake is not considered tumor unless biopsy is done |
|
Partial metabolic response: “significant reduction in SUV in tumors” |
Noncomplete response: diffuse or focal uptake exceeding mediastinal blood pool if >2 cm in size; in nodes < 2 cm diameter, uptake of 18F-FDG greater than background is positive; lesions > 1.5 cm in size in liver or spleen with uptake equal to or greater than spleen are considered tumor |
|
SMD: “no visible change in metabolic activity of tumors” |
Partial remission: see Table 3
|
|
Progressive metabolic disease: “increase in intensity or extent of tumor metabolic activity or new sites” |
Progressive disease: see Table 3
|
